- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/00 - Drugs for disorders of the endocrine system
Patent holdings for IPC class A61P 5/00
Total number of patents in this class: 762
10-year publication summary
|
19
|
57
|
48
|
45
|
63
|
49
|
56
|
51
|
45
|
42
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2700 |
10 |
| Albireo AB | 173 |
10 |
| Taisho Pharmaceutical Co., Ltd. | 847 |
10 |
| Novartis AG | 10172 |
9 |
| Amgen Inc. | 4486 |
7 |
| MSD K.K. | 64 |
7 |
| Neurocrine Biosciences, Inc. | 470 |
7 |
| Crinetics Pharmaceuticals, Inc. | 139 |
7 |
| Spruce Biosciences, Inc. | 49 |
7 |
| F. Hoffmann-La Roche AG | 7792 |
6 |
| Duke University | 3191 |
6 |
| The University of Queensland | 651 |
6 |
| OMASS Therapeutics Limited | 15 |
6 |
| Société des Produits Nestlé S.A. | 10057 |
5 |
| Genentech, Inc. | 4147 |
5 |
| Daiichi Sankyo Company, Limited | 1894 |
5 |
| Eli Lilly and Company | 4135 |
5 |
| Sumitomo Dainippon Pharma Co., Ltd. | 210 |
5 |
| Mironid Limited | 23 |
5 |
| Sanofi | 4332 |
5 |
| Other owners | 629 |